Quality of life in hypertension management using olmesartan in primary care

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 10, 2008, Pages 1641-1653

  Schmidt, André C ^a   Bramlage, Peter ^b   Limberg, Roger ^c   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c Berlin Chemie AG   (Germany)

Author keywords

Adherence; Blood pressure lowering; Compliance; Olmesartan; Persistence; Quality of life; Renin angiotensin system; SF 12

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OLMESARTAN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; FEMALE; FOLLOW UP; HEART RATE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PULSE PRESSURE; PULSE RATE; QUALITY OF LIFE; QUESTIONNAIRE; SHOCK; TACHYCARDIA; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; HEALTH STATUS; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MENTAL HEALTH; MIDDLE AGED; PRIMARY HEALTH CARE; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TETRAZOLES;

EID: 48049086750     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.10.1641     Document Type: Article

References (38)

1. Kullman S, Svardsudd K. Differences in perceived symptoms/quality of life in untreated hypertensive and normotensive men. Scand J Prim Health Care 1990;1:47-53
2. Battersby C, Hartley K, Fletcher AF, et al. Quality of life in treated hypertension: a case-control community based study. J Hum Hypertens 1995;9(12):981-6
3. Schoenberger JA, Croog SH, Sudilovsky A, et al. Self-reported side effects from antihypertensive drugs. A clinical trial. Quality of Life Research Group. Am J Hypertens 1990;3(2):123-32
4. Siegrist J, Matschinger H, Motz W. Untreated hypertensives and their quality of life. J Hypertens Suppl 1987;5(1):S15-20
5. Kjellgren KI, Ahlner J, Dahlof B, et al. Perceived symptoms amongst hypertensive patients in routine clinical practice - a population-based study. J Intern Med 1998;244(4):325-32
6. Muller A, Montoya P, Schandry R, Hartl L. Changes in physical symptoms, blood pressure and quality of life over 30 days. Behav Res Ther 1994;32(6):593-603
7. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118(8):622-9
8. Fitzpatrick R, Fletcher A, Gore S, et al. Quality of life measures in health care. I. Applications and issues in assessment. BMJ 1992;305(6861):1074-7
9. Weinberger M, Kirkman MS, Samsa GP, et al. The relationship between glycemic control and health-related quality of life in patients with non-insulin-dependent diabetes mellitus. Med Care 1994;32(12):1173-81
10. Beto JA, Bansal VK. Quality of life in treatment of hypertension. A metaanalysis of clinical trials. Am J Hypertens 1992;5(3):125-33
11. Cote I, Gregoire JP, Moisan J, Chabot I. Quality of life in hypertension: the SF-12 compared to the SF-36. Can J Clin Pharmacol 2004;11(2):e232-8
12. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34(3):220-33
13. Pickard AS, Johnson JA, Penn A, et al. Replicability of SF-36 summary scores by the SF-12 in stroke patients. Stroke 1999;30(6):1213-7
14. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infiarction and stroke: a new preventive strategy. Health Technol Assess 2003;7(31):1-94
15. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3(5):283-91, 318
16. Schmidt AC, Bramlage P, Lichtenthal A, et al. Socio-economic status and the therapeutic effectiveness of antihypertensive treatment - the design of the LEO study. Curr Med Res Opin 2007;23(8):1987-95
17. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Invest 2007;27(8):545-58
18. Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in patients with hypertension/prehypertension. Headache 2006;46(3):503-7
19. Bullinger M and Kirchberger I. SF-36 Fragebogen zum Gesundheitszustand. Hogrefe Verlag, Göttingen; 1998
20. Ellert U, Bellach BM. Der SF-36 im Bundes-Gesundheitssurvey - Beschreibung einer aktuellen Normstichprobe [SF-36 Questionnaire in the Federal Health Survey - Description]. Gesundheitswesen 1999;61(Suppl 2):184-90
21. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289(19):2560-71
22. Sharma AM, Wittchen HU, Kirch W. et al. High prevalence and poor control of hypertension in primary care: cross-sectional study. J Hypertens 2004;22(3):479-86
23. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43(1):10-7
24. Thamm M. Blood pressure in Germany - current status and trends. Gesundheitswesen 1999;61:S90-3
25. Conlin PR, Gerth WC, Fox J, et al. Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other antihypertensive drug classes. Clin Ther 2001;23(12):1999-2010
26. Tedesco MA, Ratti G, Mennella S, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12(11 Pt 1):1130-4
27. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005;18(8):1060-6
28. Rake EC, Breeze E, Fletcher AE. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo. J Hum Hypertens 2001;15(12):863-7
29. Badia X, Gutierrez F, Wiklund I, Alonso J. Validity and reliability of the Spanish version of the Psychological General Well-Being Index. Qual Life Res 1996;5(1):101-8
30. Weber MA, Bakris GL, Neutel JM, et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2003;5(5):322-9
31. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986;314(26):1657-64
32. Kochar M, Guthrie R, Triscari J, et al. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999;12(8 Pt 1):797-805
33. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16(8):569-75
34. Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005;14(11):795-803
35. Bramlage P, Pittrow D, Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care. Curr Med Res Opin 2004;20(10):1625-31
36. Wiklund I, Halling K, Ryden-Bergsren T, Fletcher A. Does lowering the blood pressure improve the mood? Quality-of-life results from the Hypertension Optimal Treatment (HOT) study. Blood Press 1997;6(6):357-64
37. Weir MR, Prisant LM, Papademetriou V, et al. Antihypertensive therapy and quality of life. Influence of blood pressure reduction, adverse events, and prior antihypertensive therapy. Am J Hypertens 1996;9(9):854-9
38. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20(4):671-81